A systematic review on the effect of bevacizumab in exudative age-related macular degeneration

  • Christine SchmuckerEmail author
  • Gerd Antes
  • Monika Lelgemann
Letter to the Editor

Dear Editor,

We read with great interest the review article entitled "A systematic review on the effect of bevacizumab in exudative age-related macular degeneration" by Schouten et al. which was published in Graefe's Archive for Clinical and Experimental Ophthalmology (2009) 247:1–11.

However, we have a few concerns about the scientific reliability and validity of the findings of this review.

Schouten et al. evaluated whether the existing evidence justifies the intravitreal and intravenous use of bevacizumab in exudative age-related macular degeneration (AMD). In this context, efficacy and safety of off-label bevacizumab was assessed.

The authors conclude that bevacizumab is effective in improving visual acuity, and that its effect is likely to be equivalent to ranibizumab. Furthermore, they state that severe adverse events for bevacizumab are rare in the short term. The conclusion of this systematic review is based on three randomised controlled trials (RCTs) and 23 before-and-after...


Age-related macular degeneration Bevacizumab Efficacy Safety 


  1. 1.
    Bashshur ZF, Schakal A, Hamam RN, El Haibi CP, Jaafar RF, Noureddin B (2007) Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 125:1357–1361CrossRefPubMedGoogle Scholar
  2. 2.
    Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:57–69CrossRefPubMedGoogle Scholar
  3. 3.
    Lazic R, Gabric N (2007) Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245:68–73CrossRefPubMedGoogle Scholar
  4. 4.
    Hahn R, Sacu S, Michels S, Varga A, Weigert G, Geitzenauer W, Vecsei-Marlovits P, Schmidt-Erfurth U (2007) Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macular degenereation. Ophthalmologe 104:588–593CrossRefPubMedGoogle Scholar
  5. 5.
    Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431CrossRefPubMedGoogle Scholar
  6. 6.
    Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ, Pan American Collaborative Retina Group (PACORES) (2008) Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246:81–87CrossRefPubMedGoogle Scholar
  7. 7.
    Fung AE, Rosenfeld PJ, Reichel E (2006) The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90:1344–1349CrossRefPubMedGoogle Scholar
  8. 8.
    IVAN Study. ISRCTN92166560. Accessed July 30, 2009
  9. 9.
    CATT Study. NCT00593450. Accessed July 30, 2009
  10. 10.
    EQUAL Study. NTR1331. Accessed July 30, 2009
  11. 11.
    VIBERA Study. NCT00559715. Accessed July 30, 2009

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Christine Schmucker
    • 1
    Email author
  • Gerd Antes
    • 1
  • Monika Lelgemann
    • 2
  1. 1.German Cochrane CentreUniversity Medical Centre FreiburgFreiburgGermany
  2. 2.Health Technology Assessment CentreUniversity BremenBremenGermany

Personalised recommendations